108 related articles for article (PubMed ID: 12017217)
1. Efficacy and tolerability of low-dose transdermal estrogen (Oesclim) in the treatment of menopausal symptoms.
Gadomska H; Barcz E; Cyganek A; Leocmach Y; Chadha-Boreham H; Marianowski L
Curr Med Res Opin; 2002; 18(2):97-102. PubMed ID: 12017217
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a low-dose of Oesclim (25 mcg daily) in the management of symptomatic menopausal women: a French open-label study.
Elia D; Tamborini A; Leocmach Y; Chadha-Boreham H
Curr Med Res Opin; 2000; 16(2):94-106. PubMed ID: 10893653
[TBL] [Abstract][Full Text] [Related]
3. OESCLIM: pre-clinical and clinical profile.
Guy M
Maturitas; 1999 Nov; 33 Suppl 1():S49-55. PubMed ID: 10661615
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
[TBL] [Abstract][Full Text] [Related]
5. OESCLIM: an advanced delivery system for HRT.
Munoz A
Maturitas; 1999 Nov; 33 Suppl 1():S39-47. PubMed ID: 10661614
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
[TBL] [Abstract][Full Text] [Related]
7. The long-term tolerability and efficacy of OESCLIM: results of a 1-year study.
Taurelle R; L'Hermite M; Haenggi W; Lauritzen C; Studd JW
Maturitas; 1999 Nov; 33 Suppl 1():S73-81. PubMed ID: 10661618
[TBL] [Abstract][Full Text] [Related]
8. OESCLIM: summary of tolerability and safety.
Brackman F
Maturitas; 1999 Nov; 33 Suppl 1():S83-8. PubMed ID: 10661619
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
[TBL] [Abstract][Full Text] [Related]
10. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems.
Guichard JP; Sauron R; Jones AB
J Clin Pharmacol; 1999 Aug; 39(8):811-6. PubMed ID: 10434233
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system.
Raynaud JP; Lévrier M; Calaf J; Laur C; Pélissier C
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):309-18. PubMed ID: 15860275
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
Adler G; Young D; Galant R; Quinn L; Witchger MS; Maki KC
Gynecol Obstet Invest; 2005; 59(4):212-9. PubMed ID: 15753617
[TBL] [Abstract][Full Text] [Related]
14. Estradiol-intranasal: a review of its use in the management of menopause.
Dooley M; Spencer CM; Ormrod D
Drugs; 2001; 61(15):2243-62. PubMed ID: 11772138
[TBL] [Abstract][Full Text] [Related]
15. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy.
Hirvonen E; Lamberg-Allardt C; Lankinen KS; Geurts P; Wilén-Rosenqvist G
Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():19-25. PubMed ID: 9389779
[TBL] [Abstract][Full Text] [Related]
16. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
[TBL] [Abstract][Full Text] [Related]
18. Treatment of menopausal symptoms with three low-dose continuous sequential 17β-estradiol/progesterone parenteral monthly formulations using novel non-polymeric microsphere technology.
Cortés-Bonilla M; Bernardo-Escudero R; Alonso-Campero R; Francisco-Doce MT; Hernández-Valencia M; Celis-González C; Márquez-Oñate R; Chedraui P; Uribe JA
Gynecol Endocrinol; 2015 Jul; 31(7):552-9. PubMed ID: 26062108
[TBL] [Abstract][Full Text] [Related]
19. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
20. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]